AGRX Stock Price, Agile Therapeutics Inc Quote, Chart

Market Summary

USD0.400.00

Market Closed

0.00%

AGRX Stock Price

View Fullscreen

AGRX RSI Chart

AGRX Valuation

Market Cap

2.7M

Price/Earnings (Trailing)

-0.19

Price/Sales (Trailing)

0.14

EV/EBITDA

-0.13

Price/Free Cashflow

-0.29

AGRX Price/Sales (Trailing)

AGRX Profitability

Operating Margin

54.18%

EBT Margin

-73.84%

Return on Equity

88.65%

Return on Assets

-141.06%

Free Cashflow Yield

-349.21%

AGRX Fundamentals

AGRX Revenue

Revenue (TTM)

19.6M

Rev. Growth (Yr)

-9.54%

Rev. Growth (Qtr)

-45.74%

AGRX Earnings

Earnings (TTM)

-14.5M

Earnings Growth (Yr)

-13.72%

Earnings Growth (Qtr)

-459.32%

Breaking Down AGRX Revenue

Last 7 days

5.3%

Last 30 days

8.1%

Last 90 days

-74.7%

Trailing 12 Months

-93.9%

How does AGRX drawdown profile look like?

AGRX Financial Health

Current Ratio

0.46

Debt/Equity

-0.09

Debt/Cashflow

-6.32

AGRX Investor Care

Shares Dilution (1Y)

635.57%

Diluted EPS (TTM)

-8.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.9M	16.3M	20.0M	19.6M
2022	5.7M	6.7M	8.4M	10.9M
2021	1.6M	2.5M	3.3M	4.1M
2020	0	0	0	749.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agile Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 03, 2023	coiante scott m	acquired	-	-	20,000	chief financial officer
Jun 28, 2023	gilmore geoffrey	acquired	-	-	20,216	chief administrative officer
Jun 28, 2023	welsh amy	acquired	-	-	13,500	chief commercial officer
Jun 28, 2023	altomari alfred	acquired	-	-	46,463	chief executive officer
Jun 28, 2023	conway robert g	acquired	-	-	13,500	chief supply chain officer
Jun 28, 2023	korner paul	acquired	-	-	13,500	chief medical officer
Jun 08, 2023	fischer seth h. z.	acquired	-	-	935	-
Jun 08, 2023	torrente josephine	acquired	-	-	935	-
Jun 08, 2023	hubbard john w	acquired	-	-	935	-
Jun 08, 2023	carson sandra	acquired	-	-	935	-

Which funds bought or sold AGRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	sold off	-100	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	39,930	39,930	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-4,988	21,144	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-4.00	20.00	-%
Feb 14, 2024	COMERICA BANK	unchanged	-	-2.00	8.00	-%
Feb 14, 2024	INVESTOR AB	new	-	3,420	3,420	-%
Feb 14, 2024	Royal Bank of Canada	added	214	1,000	2,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	50.07	6,624	37,532	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	115,000	115,000	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-20.00	88.00	-%

Are Funds Buying or Selling AGRX?

Are funds buying AGRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGRX

No. of Funds

Unveiling Agile Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	lind global fund ii lp	1.8%	44,750	SC 13G/A
Feb 06, 2024	intracoastal capital, llc	0.9%	23,961	SC 13G/A
Feb 14, 2023	perceptive advisors llc	0%	0	SC 13G/A
Feb 13, 2023	lind global fund ii lp	9.9%	4,459,759	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	6.3%	2,730,000	SC 13G/A
Jul 12, 2022	lind global fund ii lp	9.9%	3,250,223	SC 13G
Jul 11, 2022	intracoastal capital, llc	9.99%	3,430,345	SC 13G
Feb 14, 2022	perceptive advisors llc	17.5%	21,294,485	SC 13G/A
Feb 09, 2022	vanguard group inc	3.70%	4,494,704	SC 13G/A
Jul 12, 2021	blackrock inc.	1.5%	1,308,650	SC 13G/A

Recent SEC filings of Agile Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 25, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report
Feb 23, 2024	8-K	Current Report
Feb 23, 2024	424B5	Prospectus Filed
Feb 23, 2024	424B5	Prospectus Filed
Feb 15, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Agile Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	352.0B	85.2B	-7.49%	-10.35%	10.01	4.13	6.46%	95.94%
MRK	332.3B	60.1B	-0.42%	13.93%	910.36	5.53	1.40%	-97.49%
AMGN	144.7B	28.2B	-5.70%	12.33%	21.54	5.13	7.09%	2.52%
PFE	143.3B	46.5B	-8.64%	-34.49%	-103.22	3.08	42.59%	-114.62%
GILD	81.5B	27.1B	-10.34%	-21.65%	14.4	3.01	-0.60%	23.36%
TEVA	15.4B	15.8B	-4.37%	61.97%	-26.83	0.97	6.17%	76.47%
MID-CAP
PRGO	4.3B	4.7B	1.49%	-12.83%	-340.71	0.93	4.58%	90.97%
ALKS	4.1B	1.7B	-9.36%	-12.84%	11.6	2.48	49.61%	324.78%
BHC	3.2B	8.8B	-16.97%	22.33%	-5.38	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.51%	13.03%	14.38	3.07	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-28.23%	-25.52%	-3.91	1.85	24.65%	80.36%
TXMD	21.5M	1.3M	-17.33%	-48.76%	-2.09	16.47	-98.14%	-109.18%
ACRX	17.8M	-	-4.55%	55.56%	-0.97	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	8.11%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	906.7K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Agile Therapeutics Inc News

Latest updates

Agile Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-45.7%	3,614,500	6,662,000	5,503,000	3,813,000	3,995,500	3,002,000	2,126,000	1,761,000	1,513,500	1,287,000	1,185,000	116,000	749,000
Cost Of Revenue	-11.5%	2,191,000	2,477,000	2,307,000	2,003,000	1,653,000	1,425,000	2,231,000	1,527,000	5,701,000	2,711,000	1,145,000	1,161,000	-
Gross Profit	-66.0%	1,423,500	4,185,000	3,196,000	1,810,000	2,342,500	1,577,000	-105,000	234,000	-4,187,500	-1,424,000	40,000	-1,045,000	467,000
Operating Expenses	-33.1%	5,474,500	8,185,000	8,322,000	8,518,000	9,220,000	20,285,000	11,293,000	15,807,000	18,170,500	14,350,000	16,691,000	15,177,000	17,208,000
S&GA Expenses	-22.3%	3,729,000	4,800,000	4,570,000	4,670,000	6,845,500	5,560,000	7,411,000	10,553,000	13,004,500	9,386,000	11,977,000	9,253,000	10,669,500
R&D Expenses	-92.3%	54,000	705,000	703,000	763,000	352,000	788,000	856,000	1,257,000	1,673,000	1,593,000	862,000	2,123,000	3,012,000
EBITDA Margin	-7.5%	-0.66	-0.61	-1.02	-1.31	-2.36	-4.79	-7.59	-10.97	-15.87	-19.09	-25.49	-35.27	-64.94
Interest Expenses	-10.7%	304,500	341,000	372,000	402,000	432,000	1,004,000	823,000	872,000	1,000,000	999,000	993,000	922,000	904,000
Income Taxes	-	-	-	-	-	-	-	-	-4,675,000	-	-	-	-	-
Earnings Before Taxes	-459.3%	-4,468,500	-799,000	-3,809,000	-5,390,000	-3,930,000	-5,930,000	-5,168,000	-15,060,000	-19,530,000	-16,772,000	-17,637,000	-17,128,000	-17,620,000
EBT Margin	-5.9%	-0.74	-0.70	-1.17	-1.58	-2.76	-5.44	-8.45	-12.01	-17.33	-20.72	-27.45	-37.91	-69.23
Net Income	-459.3%	-4,469,000	-799,000	-3,809,000	-5,389,000	-3,930,000	-5,930,000	-5,168,000	-10,385,000	-19,530,000	-16,772,000	-17,637,000	-17,128,000	-17,620,000
Net Income Margin	-5.9%	-0.74	-0.70	-1.17	-1.58	-2.33	-4.88	-7.75	-11.19	-17.33	-20.72	-27.45	-37.91	-69.23
Free Cashflow	-52.9%	172,000	365,000	-8,519,000	-1,595,000	-1,559,000	-16,703,000	-2,941,000	-14,877,000	-16,673,000	-18,645,000	-15,414,000	-14,739,000	-17,399,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.8%	10.00	11.00	13.00	14.00	14.00	18.00	33.00	29.00	39.00	37.00	52.00	59.00	73.00	89.00	103	109	50.00	34.00	25.00	26.00	22.00
Current Assets	-5.3%	10.00	10.00	12.00	11.00	11.00	15.00	18.00	14.00	24.00	22.00	37.00	44.00	57.00	73.00	89.00	95.00	35.00	20.00	11.00	12.00	8.00
Cash Equivalents	-11.0%	3.00	3.00	3.00	4.00	5.00	6.00	13.00	4.00	19.00	15.00	26.00	16.00	14.00	24.00	39.00	94.00	34.00	18.00	11.00	12.00	8.00
Inventory	13.6%	3.00	2.00	3.00	2.00	1.00	2.00	2.00	3.00	1.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-	-
Net PPE	-25.7%	0.00	0.00	0.00	0.00	0.00	0.00	12.00	12.00	12.00	13.00	13.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00
Liabilities	14.0%	27.00	23.00	25.00	23.00	20.00	21.00	30.00	35.00	35.00	26.00	28.00	24.00	24.00	23.00	22.00	18.00	4.00	3.00	3.00	3.00	2.00
Current Liabilities	18.5%	21.00	18.00	15.00	19.00	13.00	12.00	29.00	26.00	29.00	10.00	12.00	9.00	7.00	7.00	6.00	3.00	4.00	2.00	2.00	1.00	2.00
Long Term Debt	-	2.00	-	-	-	1.00	-	-	-	-	16.00	16.00	16.00	16.00	16.00	16.00	15.00	-	-	-	-	-
LT Debt, Current	-4.7%	2.00	2.00	2.00	2.00	1.00	1.00	13.00	12.00	17.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-16.32	-	-	-	-5.54	6.00	2.00	3.00	4.00	11.00	25.00	35.00	49.00	66.00	81.00	91.00	46.00	0.00	273	271	20.00
Retained Earnings	-1.1%	-423	-418	-417	-414	-408	-404	-398	-393	-383	-363	-346	-329	-312	-295	-279	-268	-260	-254	-249	-246	-241
Additional Paid-In Capital	0.1%	407	406	406	405	403	402	401	388	387	374	372	364	362	361	360	359	306	286	273	271	262
Accumulated Depreciation	-	0.00	-	-	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	30.1%	3.00	2.00	2.00	1.00	1.00	0.00	-	-	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	5.00	-	-	-	14.00	-	-	-	101	-	-	-	197	-	-	-	52.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-52.9%	172	365	-8,519	-1,595	-1,559	-16,703	-2,934	-14,751	-16,618	-18,580	-15,336	-14,668	-17,342	-15,320	-6,765	-7,884	-3,270	-5,080	-2,378	-4,961	-3,136
Share Based Compensation	28.2%	563	439	481	498	524	536	669	764	866	887	843	742	711	647	839	621	415	378	479	490	803
Cashflow From Investing	-	-	-	-	-	-	-	-7.00	-126	-55.00	4,935	18,395	16,185	7,527	-173	-47,880	-164	-68.00	-	-	-	-
Cashflow From Financing	-75.2%	-487	-278	6,875	778	660	9,821	12,225	-523	21,081	2,262	6,595	484	115	210	166	67,494	19,447	12,894	1,404	8,670	-5,939

AGRX Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statements of Operations and Comprehensive Loss
Revenues, net	$ 19,593	$ 10,884	$ 4,101
Cost of product revenues	8,978	6,836	10,718
Gross profit	10,615	4,048	(6,617)
Operating expenses:
Research and development	2,225	3,253	6,246
Selling and marketing	17,769	30,369	43,444
General and administrative	10,505	11,860	14,698
Loss on disposition of assets		11,122
Total operating expenses	30,499	56,604	64,388
Loss from operations	(19,884)	(52,556)	(71,005)
Other income (expense)
Interest income	78	80	25
Interest expense	(1,419)	(3,131)	(3,914)
Unrealized gain on warrant liability	6,760	25,520	3,827
Total other income (expense), net	5,419	22,469	(62)
Loss before benefit from income taxes	(14,465)	(30,087)	(71,067)
Benefit from income taxes		4,675
Net loss	$ (14,465)	$ (25,412)	$ (71,067)
Net loss per share (basic) (in dollars per share)	$ (6.71)	$ (58.79)	$ (1,464.20)
Net loss per share (diluted) (in dollars per share)	$ (6.71)	$ (58.79)	$ (1,464.20)
Weighted-average common shares (basic) (in shares)	2,156,726	432,219	48,536
Weighted-average common shares (diluted) (in shares)	2,156,726	432,219	48,536
Comprehensive loss:
Net loss	$ (14,465)	$ (25,412)	$ (71,067)
Other comprehensive income:
Unrealized (loss) on marketable securities			(3)
Comprehensive loss	$ (14,465)	$ (25,412)	$ (71,070)

AGRX Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,557	$ 5,246
Accounts receivable, net	3,392	3,377
Inventory, net	2,738	1,332
Prepaid expenses and other current assets	843	1,403
Total current assets	9,530	11,358
Property and equipment, net	75	177
Right of use asset	412	695
Other non-current assets	238	2,012
Total assets	10,255	14,242
Current liabilities:
Long-term debt, current portion	1,515	1,426
Notes payable, current portion	191
Accounts payable	9,574	7,734
Accrued expenses	9,131	3,908
Lease liability, current portion	366	319
Total current liabilities	20,777	13,387
Lease liabilities, long-term	100	466
Warrant liability	5,696	5,934
Total liabilities	26,573	19,787
Commitments and contingencies (Note 12)
Stockholders' deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2023 and no shares issued and outstanding at December 31, 2022
Common stock, $0.0001 par value, 300,000,000 shares authorized, 2,963,657 and 859,402 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	4
Additional paid-in capital	406,846	403,157
Accumulated deficit	(423,168)	(408,702)
Total stockholders' deficit	(16,318)	(5,545)
Total liabilities and stockholders' deficit	$ 10,255	$ 14,242

About Agile Therapeutics Inc

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

CEO	Mr. Alfred F. Altomari
WEBSITE	agiletherapeutics.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	22

Agile Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Agile Therapeutics Inc? What does AGRX stand for in stocks?

AGRX is the stock ticker symbol of Agile Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agile Therapeutics Inc (AGRX)?

As of Fri Apr 26 2024, market cap of Agile Therapeutics Inc is 2.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers.

What is the fair value of AGRX stock?

You can check AGRX's fair value in chart for subscribers. The fair value of Agile Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agile Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agile Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGRX is over valued or under valued. Whether Agile Therapeutics Inc is cheap or expensive depends on the assumptions which impact Agile Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGRX.

What is Agile Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, AGRX's PE ratio (Price to Earnings) is -0.19 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGRX PE ratio will change depending on the future growth rate expectations of investors.